Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Heart failure with preserved left ventricular ejection fraction (HFpEF) is a syndrome
associated with high morbidity and mortality rates. Systemic low-grade inflammation is
acknowledged to be a fundamental pathophysiological mechanism of HFpEF. Interventions
targeting inflammatory pathway is understudied in HFpEF. Colchicine is a safe and well
tolerated anti-inflammatory drug, which interferes with several steps in the inflammatory
process. The drug has been extensively studied in different cardiovascular pathologies except
HFpEF. We assume that colchicine decreases inflammation and reduces sST2 levels in HFpEF.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
I.M. Sechenov First Moscow State Medical University